POSITIVE TOPLINE DATA ANNOUNCED

A Phase 3 Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC

A Phase 1/2 trial in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, Opdivo® (nivolumab) in RCC

There are currently no events to display.

AVEO TIVO-3 Topline Data Conference Call
Monday, November 5, 2018 at 5:00 p.m. Eastern Time

Leerink Partners Roundtable Series: Rare Disease & Oncology
Wednesday, October 3, 2018 at 1:00 p.m. Eastern Time

2018 Cantor Global Healthcare Conference
Tuesday, October 2, 2018 at 4:00 p.m. Eastern Time

AVEO Oncology Announces $2M Milestone Payment from EUSA Pharma Related to German Commercialization of FOTIVDA®
November 15, 2018

AVEO Reports Third Quarter 2018 Financial Results and Provides Business Update
November 9, 2018

AVEO Oncology Announces Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma Meets Primary Endpoint
November 5, 2018